Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GLMD Galmed Pharmaceuticals
0.419
-0.009-2.21%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-13.3% -75.701% -37.67% -76.373% -68.18% -87.966% -68.18% -87.966%
ROE
-15.92% -76.222% -42.25% -76.833% -72.34% -86.985% -72.34% -86.985%
ROA
-12.12% -65.989% -35.71% -65.593% -64.25% -72.971% -64.25% -72.971%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- 5.83% -54.791% -- --
ROA 5 Year Average
-- -- -- -- 4.33% -45.565% -- --
Average 5 Years ROIC
-- -- -- -- 5.39% -56.108% -- --
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-8.45% 0.647% 40.53% 0.751% 53.5% 0.751% 53.5% 0.751%
Total Assets to Common Equity
-2.11% 113.823% 8.7% 123.927% 1.17% 120.028% 1.17% 120.028%
Debt to Asset Ratio
-8.45% 0.647% 40.53% 0.751% 53.5% 0.751% 53.5% 0.751%
Current Ratio
14.97% 8.4756 -37.13% 5.2593 -5.16% 6.1327 -5.16% 6.1327
Quick Ratio
14.65% 8.4339 -37.25% 5.2391 -6.67% 5.9354 -6.67% 5.9354
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
CEO: Baharaff, Allen
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top